{"filing":{"accession_number":"0001125345-26-000045","cik":"0001125345","ticker":"MGNX","company_name":"MACROGENICS INC","form":"8-K","filing_date":"2026-07-07","report_date":null,"primary_document":"mgnx-20260630.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1125345/000112534526000045/mgnx-20260630.htm"},"events":[{"id":16450,"run_id":14703,"accession_number":"0001125345-26-000045","anchor_item_number":"2.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.97,"summary":"MacroGenics completed the sale of its GMP manufacturing operations and CDMO business to Bora Pharmaceuticals for $122.5 million in cash (plus up to $5 million in contingent consideration) effective June 30, 2026. The transaction involves the transfer of approximately 140 employees and two manufacturing facilities, representing a material disposition of a significant business segment and a strategic shift toward a clinical-stage company focused on internal pipeline development.","company_name":"MACROGENICS INC","ticker":"MGNX","filing_date":"2026-07-07","form":"8-K","submitted_at":null,"items":[{"id":14549,"accession_number":"0001125345-26-000045","item_number":"2.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"MacroGenics completed the sale of its GMP manufacturing operations and CDMO business to Bora Pharmaceuticals for $122.5 million in cash (before transaction fees and subject to post-closing adjustments), effective June 30, 2026. This is a material disposition of a significant business segment, with approximately 140 employees transferring to the buyer and the transfer of two manufacturing facilities. The transaction is disclosed under Item 2.01 (Completion of Acquisition or Disposition of Assets) and represents a material strategic shift for the company from a vertically integrated biopharmaceutical manufacturer to a clinical-stage company focused on internal pipeline development.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T20:30:49.710636+00:00","company_name":"","ticker":null,"filing_date":""},{"id":14550,"accession_number":"0001125345-26-000045","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"MacroGenics completed the sale of its GMP manufacturing operations and CDMO business to Bora Pharmaceuticals for $122.5 million in cash (plus up to $5 million in contingent consideration), with the transaction closing on June 30, 2026. The press release explicitly announces \"completion of the sale\" and the pro forma financial statements show material adjustments to the company's balance sheet and operations, including elimination of manufacturing revenues and costs. This is a material disposition of a business segment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T20:30:49.710636+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14549,"accession_number":"0001125345-26-000045","item_number":"2.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"MacroGenics completed the sale of its GMP manufacturing operations and CDMO business to Bora Pharmaceuticals for $122.5 million in cash (before transaction fees and subject to post-closing adjustments), effective June 30, 2026. This is a material disposition of a significant business segment, with approximately 140 employees transferring to the buyer and the transfer of two manufacturing facilities. The transaction is disclosed under Item 2.01 (Completion of Acquisition or Disposition of Assets) and represents a material strategic shift for the company from a vertically integrated biopharmaceutical manufacturer to a clinical-stage company focused on internal pipeline development.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T20:30:49.710636+00:00","company_name":"MACROGENICS INC","ticker":"MGNX","filing_date":"2026-07-07"},{"id":14550,"accession_number":"0001125345-26-000045","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"MacroGenics completed the sale of its GMP manufacturing operations and CDMO business to Bora Pharmaceuticals for $122.5 million in cash (plus up to $5 million in contingent consideration), with the transaction closing on June 30, 2026. The press release explicitly announces \"completion of the sale\" and the pro forma financial statements show material adjustments to the company's balance sheet and operations, including elimination of manufacturing revenues and costs. This is a material disposition of a business segment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T20:30:49.710636+00:00","company_name":"MACROGENICS INC","ticker":"MGNX","filing_date":"2026-07-07"}]}